Founded in 2018, RedCloud Bio is an innovative biotech company integrating new technologies to advance small molecule drug discovery and development. The company has laboratories in Shanghai, Beijing and Xiamen, with its own small molecule drug research platform built upon structural pharmacology, molecular dynamics and AI technologies. With these capabilities, RedCloud Bio has accumulated structural data and algorithm models covering clinically important kinase targets, and has built an innovative pipeline targeting tumor resistance, rare disease and other critical diseases with high unmet medical needs. Its lead therapeutic candidate, H002, is a small molecule next generation TKI addressing EGFR activating mutations in NSCLC, expected to enter global clinical trials shortly.
Company Details
- Employees
- 1
- Founded
- -
- Address
- Shanghai, Cn
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.redcloudbio.com/en/
- Keywords
- QIMP.
- HQ
- Shanghai
Redcloud Bio Questions
Redcloud Bio's website is http://www.redcloudbio.com/en/
Redcloud Bio's LinkedIn profile is https://cn.linkedin.com/company/redcloud-bio
Redcloud Bio has
1 employees.
View email and phone details for 1
employees at Redcloud Bio.
Redcloud Bio's industry is
Biotechnology Research
Redcloud Bio's top competitors are
Synthra Gmbh,
Hoy Scandinavian Aps,
Medblue Gerd Rupp,
Fontes Treinamentos,
United Well,
Alphagen Therapeutics,
Qimp,
Porter Litigation,
Cqs Consultancy Quality Solutions,
Atox.
Redcloud Bio's categories are Biotechnology Research
Redcloud Bio's founding year is 2018
